Table 1.
Baseline characteristics of patients with thymic epithelial tumor (TET) and non-small cell lung cancer (NSCLC).
| TET |
NSCLC |
|
|---|---|---|
| Characteristic | (n = 31) | (n = 60) |
| Age, median (range), yrs | 58 (26–78) | 65 (35–88) |
| Sex, n (%) | ||
| Male | 20 (64.5) | 47 (78.3) |
| Female | 11 (35.5) | 13 (21.7) |
| ECOG performance status | ||
| 1 | 31 (100) | 47 (78.3) |
| 2 | 0 | 13 (21.7) |
| Histology of TET, n (%) | ||
| Thymoma | 6 (19.4) | - |
| Thymic carcinoma | 25 (80.6) | - |
| Histology of NSCLC, n (%) | ||
| Squamous | - | 30 (50.0) |
| Non-squamous | - | 30 (50.0) |
| Tumor burden, median (range), cm | 12.4 (1.7–27.0) | 6.7 (1.5–15.7) |
| Prior autoimmune disease, n (%) | ||
| Myasthenia gravis | 1 (3.2) | 0 (0) |
| None | 30 (96.8) | 60 (100) |
| Number of prior chemotherapy line, median (range) | 2 (1–5) | 2 (0–9) |
| Anti-PD-1 agent | ||
| Pembrolizumab | 31 (100) | 42 (70.0) |
| Nivolumab | 0 | 18 (30.0) |
| PD-L1 status, n (%) | ||
| ≥ 1% | 18 (58.0) | 38 (63.3) |
| < 1% | 7 (22.6) | 11 (18.3) |
| not available | 6 (19.4) | 11 (18.3) |
ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death ligand 1.